JUNIPER PHARMACEUTICALS INC Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2011-11-10: Form 8-K; Period of report 2011-11-10; Description 7.01 Regulation FD Disclosure; Details 7.01.
- 2011-11-03: Form 8-K; Period of report 2011-11-03; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2011-09-22: Form 8-K; Period of report 2011-09-16; Description 1.01 Entry into a Material Definitive Agreement; 3.03 Material Modification to Rights of Security Holders; 7.01 Regulation FD Disclosure; Details 1.01.
- 2011-08-04: Form 8-K; Period of report 2011-08-04; Description 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure; Details 2.02.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2011-11-10 | 8-K | 2011-11-10 | 7.01 Regulation FD Disclosure | 7.01 On November 10, 2011, Columbia Laboratories, Inc. (the “Company”), issued a press release entitled, “Columbia Laboratories and Watson Pharmaceuticals Confirm FDA Advisory Committee to Review Preterm Birth NDA” (the “Press Release”). | adcomm8k.htm |
| 2011-11-03 | 8-K | 2011-11-03 | 2.02 Results of Operations and Financial Condition | 2.02 On November 3, 2011, Columbia Laboratories, Inc. (the “Company”), issued a press release entitled, “Columbia Laboratories Reports Third Quarter 2011 Financial Results” (the “Press Release”). | a2011form8k3qearnrel.htm |
| 2011-09-22 | 8-K | 2011-09-16 | 1.01 Entry into a Material Definitive Agreement; 3.03 Material Modification to Rights of Security Holders; 7.01 Regulation FD Disclosure | 1.01 On September 16, 2011, the board of directors of Columbia Laboratories, Inc. (the “Company”) approved an amendment (the “Amendment”) to the Company's Amended and Restated Rights Agreement, dated as of November 29, 2010 (the “Rights Agreement”), to extend the expiration date of the rights contained therein from March 12, 2012 to July 3, 2013. 3.03 The disclosures set forth under Item 1.01 are incorporated by reference into this Item 3.03. 7.01 A copy of the press release announcing the Amendment is furnished herewith as Exhibit 99.1. | a8-k.htm |
| 2011-08-04 | 8-K | 2011-08-04 | 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure | 2.02 On August 4, 2011, Columbia Laboratories, Inc. (the “Company”) held a conference call to discuss financial results of the quarter ended June 30, 2011. 7.01 A description of the Transcript set forth under Item 2.02 of this Current Report on Form 8-K is incorporated by reference into this item. | form8k.htm |
| 2011-08-04 | 8-K | 2011-08-04 | 2.02 Results of Operations and Financial Condition | 2.02 On August 4, 2011, Columbia Laboratories, Inc. (the “Company”), issued a press release entitled, “Columbia Laboratories Reports Second Quarter 2011 Financial Results” (the “Press Release”). | form8-k.htm |
| 2011-07-20 | 8-K | 2011-07-20 | 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | 5.03 On July 15, 2011, the Board of Directors of Columbia Laboratories, Inc. (the “Company”), approved Amended and Restated Bylaws for the Company. | a20118-kamrest.htm |
| 2011-06-27 | 8-K | 2011-06-27 | 7.01 Regulation FD Disclosure | 7.01 On June 27, 2011, Columbia Laboratories, Inc. (the “Company”), issued a press release entitled, “Columbia Laboratories' NDA for PROCHIEVE® Vaginal Progesterone Gel Accepted for Filing by FDA” (the “Press Release”). | a20118kform.htm |
| 2011-05-05 | 8-K | 2011-05-05 | 7.01 Regulation FD Disclosure | 7.01 On May 5, 2011, Columbia Laboratories, Inc. (the “Company”) held a conference call (the “Conference Call”) to discuss first quarter 2011 financial results. | a2011q18kcalltranscript.htm |
| 2011-05-05 | 8-K | 2011-05-03 | 2.02 Results of Operations and Financial Condition; 5.07 Submission of Matters to a Vote of Security Holders; 7.01 Regulation FD Disclosure; 8.01 Other Events | 2.02 On May 5, 2011, Columbia Laboratories, Inc. (the “Company”), issued a press release entitled, “Columbia Laboratories Reports First Quarter 2011 Financial Results” (the “Press Release”). 5.07 The 2011 Annual Meeting of Stockholders (the “Annual Meeting”) of the Company was held on May 3, 2011. 7.01 incorporated by reference into this item. | a20118kq1earnrelandvote.htm |
| 2011-04-26 | 8-K | 2011-04-26 | 8.01 Other Events | 8.01 On April 26, 2011, Columbia Laboratories, Inc. (the “Company”), issued a press release entitled, "Columbia Laboratories Submits NDA for PROCHIEVE® Vaginal Progesterone Gel" (the “Press Release”). | a2011form8k.htm |
| 2011-04-26 | 8-K/A | 2011-04-20 | 1.01 Entry into a Material Definitive Agreement; 1.02 Termination of a Material Definitive Agreement; 2.01 Completion of Acquisition or Disposition of Assets; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 1.02 On April 20, 2011, the Company's wholly owned subsidiary, Columbia Laboratories (Bermuda) Ltd. (“Columbia Bermuda”) entered into a letter agreement with Mipharm S.p.A. (“Mipharm”), the manufacturer of Striant, relating to the assignment of certain rights and obligations to Actient (the “U.S. Supply Agreement Assignment”). 2.01 Descriptions of the Asset Purchase Agreement and License Agreement are set forth under Item 1.01 of this Current Report on Form 8-K and are incorporated by reference into this item. 8.01 On April 20, 2011, the Company issued a press release entitled "Actient Pharmaceuticals LLC Acquires U.S. Rights to STRIANT from Columbia Laboratories". | form8ka.htm |
| 2011-04-20 | 8-K | 2011-04-20 | 1.01 Entry into a Material Definitive Agreement; 1.02 Termination of a Material Definitive Agreement; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 1.02 On April 20, 2011, the Company's wholly owned subsidiary, Columbia Laboratories (Bermuda) Ltd. (“Columbia Bermuda”) entered into a letter agreement with Mipharm S.p.A. (“Mipharm”), the manufacturer of Striant, relating to the assignment of certain rights and obligations to Actient (the “U.S. Supply Agreement Assignment”). 8.01 On April 20, 2011, the Company issued a press release entitled "Actient Pharmaceuticals LLC Acquires U.S. Rights to STRIANT from Columbia Laboratories". | form8kactientstriant.htm |
| 2011-04-08 | 8-K | 2011-04-08 | 8.01 Other Events | form8k.htm | |
| 2011-04-08 | 8-K | 2011-04-06 | 8.01 Other Events | 8.01 On April 6, 2011, Columbia Laboratories, Inc. (the “Company”), issued a press release entitled, “Columbia Laboratories and Watson Announce Publication of Positive Phase III PROCHIEVE® Vaginal Progesterone Gel Study Results” (the “Press Release”). | form8k.htm |
| 2011-03-10 | 8-K | 2011-03-10 | 2.02 Results of Operations and Financial Condition | 2.02 On March 10, 2011, Columbia Laboratories, Inc. (the “Company”), issued a press release entitled, “Columbia Laboratories Reports Fourth Quarter and Year End 2010 Financial Results” (the “Press Release”). | form8k.htm |
| 2011-03-07 | 8-K | 2011-03-07 | 7.01 Regulation FD Disclosure; 8.01 Other Events | 7.01 Frank C. Condella, Jr., president and chief executive officer of Columbia Laboratories, Inc. (the “Company”), and Lawrence A. Gyenes, the Company's senior vice president and chief financial officer, will present to various investors beginning March 7, 2011. | form8k.htm |